ArsenalBio
ArsenalBio is a clinical stage, programmable cell therapy company focused on developing treatments for solid tumor cancers.
Overview of ArsenalBio
ArsenalBio is a clinical stage, programmable cell therapy company that develops treatments targeting solid tumors. The company leverages a computationally driven approach to engineer medicines designed to combat cancer's complex and multi-faceted characteristics. The primary focus is on creating innovative therapies that precisely attack cancer cells while sparing normal tissue.
Clinical Trials and Research
ArsenalBio has launched a Phase 1/2 clinical trial named AB-2100, aimed at treating clear-cell renal cell carcinoma. This marks a significant step in the company's efforts to bring their programmable cell therapies into clinical settings. Additionally, ArsenalBio presented four abstracts at the ASGCT Annual Meeting, showcasing new mechanisms for leveraging CAR T cells to better address solid tumor cancers.
Key Milestones and Recognitions
In 2023, ArsenalBio earned a spot on the Endpoints 11 list, recognized as one of the top biotechs of the year. Another significant milestone was the successful closing of a $220 million Series B financing round. This funding will be instrumental in advancing the company's programmable cell therapy programs further into clinical development.
Headquarters and Locations
ArsenalBio is headquartered in South San Francisco, CA, a hub for biotechnology and healthcare innovation. The company also operates an additional location in Hayward, CA, expanding its research and operational capabilities in the Bay Area.